

Finished Product Certificate of Analysis

NDC Number:	NDC Number: 71449-091-22		2430139A		
Product Description:	Bevacizumab 2 mg/0.08 mL (25 mg/mL) Repackaged, Ophthalmic Injection, 0.08 mL in 0.25 mL Syringe				
Manufacture Date:	22JAN2024	Expiration Date:	20JUN2024		
Storage Condition:	Refrigerated Temperature (2-8°C), Protect from Light and Freezing				

Test		Method	Acceptance Criteria	Results	Pass/Fail	
Sterility		USP <71> and <1223>	No Growth	No Growth	Pass	
Post Steriliz Endotoxin	ation	USP <85>	NMT 20.0 EU/mL	<1.0 EU/mL	Pass	
Clarity		Visual	Clear	Pass	Pass	
Color		Visual	Colorless	Pass	Pass	
Visible Parti	iculates	USP <790>	Essentially free of visible particulates	Pass	Pass	
	≥10 µm		NMT 50 particles/mL	19 Particles/mL		
Particulate	≥25 µm	USP <789>	NMT 5 particles/mL	0 Particles/mL	Pass	
	≥50 µm		NMT 2 particles/mL	0 Particles/mL		

All finished product Quality Control test results met acceptance criteria. This batch is suitable for release.

Quality Control Management Disposition of the Batch:		☑ Approved □ Rejected	
Michele Kuhn	Michele Kuhn	QC Manager	07MAR2024
Print Name	Signature	Title	Date